Objective
Developing a state-transition Markov model/ Microsimulation model for the successful launch of the client’s product in Indian market. Study include the insight gathering on following pointers:
- Prevalence and incidence: Understanding the burden of beta thalassemia in India
- Estimation for health resource utilization: To estimate the annual and lifetime healthcare cost of the TDT (transfusion dependent thalassemia) population
- Estimation of resources consumed in blood transfusion, as well as the resources consumed in treating IOL (iron overload) complications
- Direct & indirect cost associated with beta thalassemia management
- Estimating costs of ICTs (iron chelating agents)
- Estimating costs of blood and instrumental monitoring, and administration costs
- Running a TDT health utilization survey among leading specialists/ haematologists nationwide
- Cost-of-illness analysis; Economic impact of beta thalassemia in India including associated treatment costs
Approach
- Thorough secondary research has been conducted through literature review and publications are selected based on the key inclusion criteria and data elements
- eQuantX conducted primary market research across India with hematologists treating beta thalassemia patients, and hospital staffs – in order to get insights for estimating resources consumed in blood transfusion, and in treating IOL (iron overload) complications to understand the cost effectiveness for the drug under evaluation
Outcome
Measured medical and other costs resulting from beta thalassemia and its economic burden to society; Determined economic impact of beta thalassemia in India by measuring and comparing the economic burdens of beta thalassemia to society, estimating the costs of illness associated with mortality, morbidity, disability, and other disease characteristics, conducting healthcare resource utilization analysis by identifying incidence or prevalence of beta thalassemia, estimation of direct and indirect expenditures that result from premature death, disability or injury due to beta thalassemia, opportunity cost of blood shortage over next 1/3/5 years and trial data analyses
